Compare Stocks → Controversial CEO explains new way to amass wealth (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AGEOTCMKTS:APLIFNASDAQ:EVOKNASDAQ:RZLTNASDAQ:SLRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGEAgeX Therapeutics$11.10-11.9%$4.54$11.07▼$35.71$11.99M1.183,849 shs3,700 shsAPLIFAppili Therapeutics$0.03$0.03$0.02▼$0.08$3.15M-0.5253,268 shs93,000 shsEVOKEvoke Pharma$0.47-4.1%$0.57$0.41▼$2.40$3.99M0.3850,792 shs8,039 shsRZLTRezolute$3.27-1.2%$2.39$0.72▼$3.69$131.23M1.29306,929 shs405,669 shsSLRXSalarius Pharmaceuticals$0.48-4.0%$0.55$0.43▼$2.31$2.30M0.9592,295 shs68,136 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGEAgeX Therapeutics0.00%0.00%0.00%+4,345.56%+2,909.66%APLIFAppili Therapeutics-7.14%-11.86%-29.54%+25.60%-2.62%EVOKEvoke Pharma-3.19%+6.82%-19.70%-37.33%-78.83%RZLTRezolute-1.21%+25.29%+38.56%+214.42%+42.17%SLRXSalarius Pharmaceuticals-3.99%-0.62%-1.84%-14.09%-73.72%Is Tesla going out of business? (Ad)Goldman Sachs estimates that this new “Future Fuel” will unleash an $11.7 trillion wave of wealth over the coming decade. That’s 10 TIMES BIGGER than the electric vehicle market. Click here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAPLIFAppili TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/ARZLTRezolute2.8383 of 5 stars3.54.00.00.00.65.00.0SLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGEAgeX TherapeuticsN/AN/AN/AN/AAPLIFAppili TherapeuticsN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/ARZLTRezolute3.00Buy$8.80169.11% UpsideSLRXSalarius Pharmaceuticals2.00HoldN/AN/ACurrent Analyst RatingsLatest AGE, SLRX, RZLT, APLIF, and EVOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/7/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/14/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGEAgeX Therapeutics$140K85.63N/AN/A($16.07) per share-0.69APLIFAppili Therapeutics$280K11.26N/AN/A($0.05) per share-0.52EVOKEvoke Pharma$5.18M0.77N/AN/A($0.77) per share-0.61RZLTRezoluteN/AN/AN/AN/A$3.15 per shareN/ASLRXSalarius Pharmaceuticals$1.84M1.25N/AN/A$1.34 per share0.36Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGEAgeX Therapeutics-$14.80M-$13.03N/A∞N/A-10,424.65%N/A-120.90%5/13/2024 (Estimated)APLIFAppili Therapeutics-$6.99M-$0.04N/AN/AN/A-456.86%N/A-229.96%6/21/2024 (Estimated)EVOKEvoke Pharma-$7.79M-$2.33N/A∞N/A-150.43%-517.99%-91.83%5/20/2024 (Estimated)RZLTRezolute-$51.79M-$1.10N/AN/AN/AN/A-51.81%-48.05%5/9/2024 (Estimated)SLRXSalarius Pharmaceuticals-$12.54M-$4.53N/AN/AN/AN/A-197.96%-135.23%5/9/2024 (Estimated)Latest AGE, SLRX, RZLT, APLIF, and EVOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/22/2024Q4 2023SLRXSalarius Pharmaceuticals-$1.01-$0.22+$0.79-$0.22N/AN/A3/14/2024Q4 2023EVOKEvoke PharmaN/A-$0.59-$0.59-$0.59N/A$1.68 million 2/13/2024Q3 2024APLIFAppili Therapeutics-$0.01-$0.01N/AN/AN/A$0.36 million2/13/2024Q2 2024RZLTRezolute-$0.27-$0.27N/A-$0.27N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGEAgeX TherapeuticsN/AN/AN/AN/AN/AAPLIFAppili TherapeuticsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGEAgeX TherapeuticsN/A0.130.36APLIFAppili TherapeuticsN/A0.460.46EVOKEvoke PharmaN/A2.252.09RZLTRezoluteN/A12.0012.00SLRXSalarius PharmaceuticalsN/A5.025.02OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGEAgeX Therapeutics12.50%APLIFAppili TherapeuticsN/AEVOKEvoke PharmaN/ARZLTRezolute82.97%SLRXSalarius Pharmaceuticals11.88%Insider OwnershipCompanyInsider OwnershipAGEAgeX Therapeutics6.50%APLIFAppili Therapeutics11.84%EVOKEvoke Pharma6.10%RZLTRezolute20.80%SLRXSalarius Pharmaceuticals3.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableAPLIFAppili Therapeutics8121.27 million106.91 millionNot OptionableEVOKEvoke Pharma48.48 million7.96 millionNot OptionableRZLTRezolute5740.13 million31.78 millionNot OptionableSLRXSalarius Pharmaceuticals24.78 million4.61 millionNot OptionableAGE, SLRX, RZLT, APLIF, and EVOK HeadlinesSourceHeadlineSalarius Pharmaceuticals (NASDAQ:SLRX) Stock Price Up 7.5%americanbankingnews.com - May 2 at 2:24 AMSLRX Pursues Important Goalfinance.yahoo.com - April 2 at 1:44 PMWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Datamsn.com - March 27 at 1:54 AMWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarketmsn.com - March 25 at 11:52 AMSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 23 at 8:07 AMSalarius: Q4 Earnings Snapshotsfgate.com - March 22 at 4:56 PMSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 22 at 4:05 PMQuoin stock craters 47% on public offering after rallying in prior sessionmsn.com - March 5 at 2:32 PMQuoin stock soars 60% on FDA update for ichthyosis drugmsn.com - March 4 at 12:43 PMSalarius Pharmaceuticals Implements Cost-savings Measuresmarkets.businessinsider.com - February 22 at 1:52 PMSalarius's CEO David Arthur steps downmsn.com - February 22 at 8:52 AMSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expensesfinance.yahoo.com - February 22 at 8:52 AMSalarius Pharmaceuticals Inc (SLRX)uk.investing.com - February 9 at 12:58 AMSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degradersfinance.yahoo.com - January 16 at 1:35 PMSquare Pharmaceuticals Ltd.wsj.com - January 13 at 3:02 PMInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollmentfinance.yahoo.com - January 3 at 9:32 AMSLRX Continues Work as it Seeks Alternativesfinance.yahoo.com - November 10 at 4:03 PMSalarius Pharmaceuticals Inc SLRXmorningstar.com - November 8 at 8:37 AMSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Programfinance.yahoo.com - November 7 at 10:25 AMSalarius Pharmaceuticals cuts half of workforce despite positive clinical developmentsbizjournals.com - August 10 at 6:57 PMSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - August 10 at 6:57 PMSLRX Pursuing Strategic Alternativesfinance.yahoo.com - August 9 at 3:15 PMSalarius Pharmaceuticals lays off over 50% of staff in search for strategic alternativesendpts.com - August 9 at 10:15 AMWatching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price Targetbenzinga.com - July 11 at 5:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHasbro’s Management Made All the Right Calls This QuarterApril 25, 2024 11:16 AMView Hasbro’s Management Made All the Right Calls This QuarterBargain Alert: 3 Large Caps With Extremely Oversold RSIsMay 3, 2024 8:57 AMView Bargain Alert: 3 Large Caps With Extremely Oversold RSIsYou Can Follow BlackRock’s Market View for Your MoneyApril 12, 2024 10:00 AMView You Can Follow BlackRock’s Market View for Your MoneyWestern Digital Slips Despite EPS Beat and Raise - Buy Time? April 29, 2024 7:45 AMView Western Digital Slips Despite EPS Beat and Raise - Buy Time? Vital Farms Rides the Pasture-Raised Egg Trend to the Bank April 15, 2024 7:40 AMView Vital Farms Rides the Pasture-Raised Egg Trend to the Bank All Headlines Company DescriptionsAgeX TherapeuticsNYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Appili TherapeuticsOTCMKTS:APLIFAppili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.Evoke PharmaNASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.RezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Salarius PharmaceuticalsNASDAQ:SLRXSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.